Interactions between Aβ and mutated Tau lead to polymorphism and induce aggregation of Aβ-mutated tau oligomeric

Yoav Raz1, Yifat Miller

  • 1Department of Chemistry, Ben‑Gurion University of the Negev, Beer-Sheva, Israel.

Plos One
|August 17, 2013
PubMed

Insights

This study investigates interactions between amyloid-beta (Aβ) and mutated tau protein in fronto-temporal dementia. Researchers modeled tau-Aβ complexes, revealing polymorphic structures with a preference for double-layer conformations.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Fronto-temporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) is characterized by neurofibrillary tangles from mutated tau protein aggregation.
  • Genetic mutations in the MAPT gene, such as ∆K280 in the tau R2 repeat, enhance tau aggregation.
  • Alzheimer's disease involves amyloid-beta (Aβ) aggregation with wild-type tau, suggesting potential interactions with mutated tau in FTDP-17.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying interactions between Aβ and mutated tau.
  • To investigate the structural characteristics of tau-Aβ oligomeric complexes.

Main Methods:

  • Construction of fourteen ∆K280 mutated tau-Aβ17-42 oligomeric complexes.
  • Modeling of complexes with hydrophobic or salt-bridge interactions in the mutated tau core.
  • Consideration of single-layer (monomer-monomer) and double-layer (oligomer-oligomer) conformations, as well as alternating trimer arrangements.

Main Results:

  • Observed polymorphic mutated tau-Aβ17-42 oligomeric complexes.
  • A slight preference for the double-layer conformation was noted.
  • Alternating arrangements of Aβ and mutated tau trimers formed stable β-structures, though energetically less favorable than other models.

Conclusions:

  • Interactions between Aβ and mutated tau can lead to diverse oligomeric complex structures.
  • The double-layer conformation appears to be a preferred structural arrangement.
  • Understanding these interactions is crucial for elucidating FTDP-17 pathogenesis.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...